Cargando…
Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42
Rac and Cdc42, are homologous GTPases that regulate cell migration, invasion, and cell-cycle progression; thus, representing key targets for metastasis therapy. We previously reported on the efficacy of MBQ-167, which blocks both Rac1 and Cdc42 in breast cancer cells and mouse models of metastasis....
Autores principales: | Medina, Julia I., Cruz-Collazo, Ailed, Maldonado, Maria del Mar, Matos Gascot, Tatiana, Borrero-Garcia, Luis D., Cooke, Mariana, Kazanietz, Marcelo G., Hernandez O'Farril, Eliud, Vlaar, Cornelis P., Dharmawardhane, Suranganie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970268/ https://www.ncbi.nlm.nih.gov/pubmed/36861094 http://dx.doi.org/10.1158/2767-9764.CRC-22-0303 |
Ejemplares similares
-
Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167
in Mice by Supercritical Fluid Chromatography–Tandem Mass Spectrometry
por: Maldonado, María del Mar, et al.
Publicado: (2019) -
Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
por: Reig-López, Javier, et al.
Publicado: (2020) -
Targeting Rac and Cdc42 GEFs in Metastatic Cancer
por: Maldonado, Maria del Mar, et al.
Publicado: (2020) -
Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models
por: Torres-Sanchez, Anamaris, et al.
Publicado: (2023) -
Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
por: Borrero-García, Luis D., et al.
Publicado: (2021)